PMID- 30056293
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20230918
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
VI  - 169
DP  - 2018 Sep
TI  - The efficacy and safety of anticoagulation in cerebral vein thrombosis: A 
      systematic review and meta-analysis.
PG  - 135-139
LID - S0049-3848(18)30440-7 [pii]
LID - 10.1016/j.thromres.2018.07.023 [doi]
AB  - BACKGROUND: Anticoagulation with unfractionated heparin (UFH) or low molecular 
      weight heparin (LMWH) is the mainstay for the treatment of patients with acute 
      cerebral vein thrombosis (CVT) with or without intracranial hemorrhage (ICH). 
      AIM: We conducted a systematic review and meta-analysis to determine the efficacy 
      and safety of LMWH compared to UFH for the treatment of acute CVT. METHODS: An 
      electronic search of MEDLINE, Pubmed, CENTRAL and Google Scholar was performed. 
      Randomized controlled trials (RCT) reporting on the efficacy and safety of 
      anticoagulation for acute treatment of CVT were included. Outcomes of interest 
      included mortality, disability, new ICH and pulmonary embolism (PE). RESULTS: 
      Overall, 4 RCTs were included in the meta-analysis. Two trials compared 
      anticoagulation (UFH (N = 1) and LMWH (N = 1)) to placebo. The use of 
      anticoagulation therapy was associated with an odd ratio (OR) for mortality and 
      disability of 0.31 (95% confidence interval (CI) 0.07 to 1.45; p = 0.14) and 0.3 
      (95% CI 0.09 to 1.01; p = 0.05), respectively. Three new ICHs were observed among 
      patients receiving placebo and no patient had a PE complication. The other two 
      trials compared LMWH to UFH. LMWH was associated with an OR for mortality and 
      disability of 0.21 (95% CI 0.02 to 2.44, p = 0.21) and 0.5 (95% CI 0.11 to 2.23; 
      p = 0.36), respectively. There were no new events of ICH or PE. CONCLUSION: LMWH 
      seems to be safe and effective for the management of acute CVT.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Al Rawahi, Bader
AU  - Al Rawahi B
AD  - Department of Hematology, Sultan Qaboos University, Sultan Qaboos University 
      Hospital, Oman. Electronic address: bass@squ.edu.om.
FAU - Almegren, Mosaad
AU  - Almegren M
AD  - Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, 
      Saudi Arabia.
FAU - Carrier, Marc
AU  - Carrier M
AD  - Department of Medicine, The Ottawa Hospital Research Institute, University of 
      Ottawa, Canada. Electronic address: mcarrier@toh.ca.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20180725
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
CIN - Thromb Res. 2019 Aug;180:28. PMID: 31176033
MH  - Acute Disease
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Heparin/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - Intracranial Hemorrhages/complications
MH  - Intracranial Thrombosis/complications/*drug therapy
MH  - Pulmonary Embolism/complications
MH  - Treatment Outcome
MH  - Venous Thrombosis/complications/*drug therapy
EDAT- 2018/07/30 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/07/30 06:00
PHST- 2018/04/19 00:00 [received]
PHST- 2018/07/11 00:00 [revised]
PHST- 2018/07/20 00:00 [accepted]
PHST- 2018/07/30 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/07/30 06:00 [entrez]
AID - S0049-3848(18)30440-7 [pii]
AID - 10.1016/j.thromres.2018.07.023 [doi]
PST - ppublish
SO  - Thromb Res. 2018 Sep;169:135-139. doi: 10.1016/j.thromres.2018.07.023. Epub 2018 
      Jul 25.